Pfizer’s Legos Lays Out Oncology Focus And Direction
Pfizer oncology head Jeff Legos tells Scrip how program cuts and a sharper focus on ADCs, bispecifics and China partnerships have strengthened the company’s cancer pipeline.
Scrip - June 12, 2026

Pipeline Watch: Fourteen Approvals And Ten Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 12, 2026

EULAR: Levicept Believes It Has The New Humira On Its Hands
The UK biotech's chief scientific officer, Simon Westbrook, told Scrip at EULAR that LEVI-04's ability to target symptoms and potentially modify the disease could unlock a mega-blockbuster for osteoarthritis.
Scrip - June 12, 2026

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda
Q1 2026 saw Eli Lilly's Mounjaro displace Merck & Co.'s Keytruda as the world's best-selling drug by quarter. Seven of the top 10 products fell from Q4 2025, partly a seasonal first-quarter effect, but made the three who made gains all the more notable.
Scrip - June 12, 2026

LongBio’s Antibody Hits Phase III Endpoint In Seasonal Allergic Rhinitis
Chinese firm LongBio Pharma’s IgE-targeted antibody may become the first anti-IgE biologic for seasonal allergic rhinitis on the China market if approved following positive Phase III results.
Scrip - June 12, 2026

Why Big Pharma Should Pay Attention To GLP-1 Drug Use Insights From Brazil
As more big pharma firms join Novo Nordisk and Eli Lilly in the obesity drug race, they might want to pay attention to consumption patterns in Brazil, South America’s largest market, that are influencing commercial, legal and regulatory decisions.
Scrip - June 12, 2026

Keep NTAP And TPT On Tap, Stakeholders Tell CMS
Stakeholders overwhelmingly oppose CMS proposals to repeal the NTAP and TPT alternate pathways for FDA breakthrough devices, warning the move would hinder hospital adoption and patient access. A separate proposal to create three new MS-DRG codes for complex spinal fusion has drawn broad support.
Medtech Insight - June 11, 2026

Resmed Pays $340m For Noctrix To Treat Sleep Disorder CPAP Was Never Built For
Resmed has spent decades treating obstructive sleep apnea. Its $340m acquisition of Noctrix Health signals something different — a deliberate move into restless legs syndrome (RLS), the third most prevalent sleep disorder in the US and one Resmed’s core technology was never designed to address.
Medtech Insight - June 11, 2026

AI Documentation Tools Named A Top Driver Of 2027 Medical Cost, PwC Finds
Ambient AI scribes are lifting physician revenue, but the same tools are intensifying coding patterns commercial payers are starting to push back on. Provider consolidation is amplifying the pressure.
Medtech Insight - June 11, 2026

Execs On The Move: June 1–5, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 11, 2026

Vague AI Literacy Requirements For Medtech Signal A Problem In Europe
Watered-down EU training obligations and growing evidence of automation bias are shifting liability risk toward device makers, experts have warned.
Medtech Insight - June 11, 2026

Endogene.bio CEO On A Menstrual-Blood Test For Endometriosis
A methylation sequencing assay on uncultured menstrual stem cells hit 79% sensitivity and 83% specificity across two independent sites — early data endogene.bio CEO María Teresa Pérez Zaballos frames as a route to molecular stratification, not just diagnosis.
Medtech Insight - June 11, 2026

Neutrogena Tapping BEMT’s ‘Aesthetic Benefits’ In Sunscreen Pipeline
Kenvue has confirmed it will integrate BEMT into Neutrogena products this year, backed by its own research into how the filter performs in combination with other approved UV filters.
HBW Insight - June 11, 2026

New EU Packaging Rules: What Consumer Healthcare Companies Need To Know
Squire Patton Boggs counsel Manon Ombredane and EUROPEN senior public affairs manager Marzia Scopelliti talked industry through the practical implications of the EU’s Packaging and Packaging Waste Regulation at the 62nd AESGP Annual Meeting in Berlin.
HBW Insight - June 11, 2026

US Consumer Health People Moves: Seed Health, SDC Nutrition, AHPA, HRG, Hello, More
Seed Health adds marketing chief; SDC has new CEO, facility; Wilson Is AHPA VP for association programs; HRG president, majority owner marks 40 years; actress puts on “aura” for hello; and Vitamin Angels names chief financial, administrative officer.
HBW Insight - June 11, 2026

New York Setting Limits For Mercury In Cosmetics, Personal Care
New York's DEC is moving to restrict mercury in cosmetics — particularly skin-lightening products — while also clarifying how companies must demonstrate compliance with the state's existing 1,4-dioxane limits.
HBW Insight - June 11, 2026

Livzon Gains Chinese Approval For Fertility Biosimilar
Livzon MABPharm has announced approval from China’s National Medical Products Administration for its recombinant human follitropin alfa solution for injection.
Generics Bulletin - June 12, 2026

Sanofi And Regeneron Signal ‘Vigorous’ Patent Defense Plans For Dupixent
Regeneron’s CFO Christopher Fenimore has outlined intentions to “extend Dupixent's marketing exclusivity for as long as we can,” as the list of upcoming biosimilar competitors keeps growing.
Generics Bulletin - June 12, 2026

Xbrane Bets On Partners To Unlock Darzalex Biosimilar
Xbrane has partnered with JOINN Biologics US to advance Xdarzane, its proposed Darzalex biosimilar, shifting further CMC and pilot-scale work to a specialist manufacturer as the Swedish developer pursues a capital-light strategy built around partnerships, licensing and retained upside.
Generics Bulletin - June 12, 2026

Streamlining Alone Will Not Fill Europe’s Biosimilar Void
Representatives from Medicines for Europe and its Biosimilar Medicines Group tell Generics Bulletin that Europe’s move away from routine comparative efficacy studies is a major step forward but not enough on its own to solve the looming biosimilar “void.”
Generics Bulletin - June 12, 2026

Fragile Scaling: The Hidden Risks When Biotech Cuts Its Way To Survival
While layoffs are treated most often as a financial lever, they are also a legal, operational and governance event that most biotechs fail to manage as such.
In Vivo - June 12, 2026